12:00 AM
 | 
Apr 14, 2003
 |  BioCentury  |  Strategy

Measuring investment

Measuring investment

Company 4/11 mkt cap FY01 R&D FY01 SG&A FY01 R&D+ SG&A FY02 R&D FY02 SG&A FY02 R&D+ SG&A $ Chg % Chg Head-count Ph II trials Ph III trials Filed On mkt Notes
Adolor (ADLR) $414.4 $36.0 $15.2 $51.2 $71.7 $21.7 $93.4 $42.2 82% 122 2 2
Alkermes (ALKS) $579.0 $68.8 $19.6 $88.4 $92.1 $24.4 $116.5 $28.1 32% 419 1 2 1 1 (A) (B)
Amylin (AMLN) $1,468.0 $49.6 $20.5 $70.1 $94.5 $25.3 $119.8 $49.7 71% 350 1 1

Read the full 702 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >